MBX MBX BIOSCIENCES INC.

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22.

The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast  or dial 1-877-407-0779 (US) or 1-201-389-0914 (international). The live and archived webcast of the call and slide presentation will be available in the Investors section of the Company’s website at /news-events/events.

About MBX Biosciences 

MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. To learn more, please visit the Company website at and follow it on .

Media Contact:

Katie Beach Oltsik

Inizio Evoke Comms



(937) 232-4889

Investor Contact:

Jim DeNike

MBX Biosciences



EN
19/09/2025

Underlying

MBXMBX BIOSCIENCES INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MBX BIOSCIENCES INC.

 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences to Participate in Upcoming March Investor Conferences

MBX Biosciences to Participate in Upcoming March Investor Conferences CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will participate in the following upcoming March investor conferences: Citizens Life Sciences Conference Date: Tuesday, ...

February 23, 2026 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences to Participate in Upcoming Investor Conferences

MBX Biosciences to Participate in Upcoming Investor Conferences CARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at and participate in the following upcoming investor conferences: 36th Oppenheimer Annual Healthcare Life Science...

February 11, 2026 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit...

MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Laurie Stelzer as an independent director on the Company’s Board of Directors and as chairperson of the board’s audit committee. Ms. Stelzer brings decades of executive and financial leadershi...

January 22, 2026 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th An...

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026 Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR t...

January 11, 2026 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare C...

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco being held on January 12-15, 2026. 44th Annual J.P. Morgan He...

December 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch